Read More
A research team at the University of Hong Kong has uncovered a key mechanism linking microtubules and chemotherapy, enhancing cancer drug efficacy and patient outcomes.
ADVERTISEMENT
SCROLL TO CONTINUE WITH CONTENT
This study highlighted the complex relationship between taxanes -- widely used chemotherapeutic drugs -- and microtubule acetylation, a process vital for cancer cell sensitivity to treatment.
Microtubules play a crucial role in cancer-related processes such as cell division and migration, making them key targets for taxanes in cancer treatment.
Current studies reveal that chemical modifications of microtubules, like acetylation, are linked to the effectiveness of paclitaxel -- a leading drug in the taxane class for treating ovarian, breast, and lung cancers.
However, the molecular mechanisms by which tubulin acetyltransferases modify microtubules and interact with paclitaxel are still not fully understood.
The research team, led by Jeff Ti Shih-Chieh, assistant professor from the School of Biomedical Sciences at HKUMed, discovered that reactions within the microtubules are inhibited by paclitaxel.
Their investigation showed that tubulin acetyltransferases utilize anchors in the taxane-binding pocket to facilitate microtubule acetylation inside the lumen.
Ti said that understanding the mechanisms of microtubule modification could lead to new therapies targeting these processes.
“For example, modulators of tubulin acetyltransferases could become powerful tools for treating diseases associated with abnormal microtubule acetylation levels, such as certain cancers and neurodegenerative disorders like Huntington’s disease and Parkinson’s disease,” he said.
This research lays the foundation for innovative treatments that could enhance patient outcomes and provide new hope for those facing various diseases.
(Cheng Wong)
